3178-03-8

Usage

Physical Appearance

Pale yellow to light brown clear liquid

Solubility

Insoluble in water, soluble in organic solvents

Primary Use

Intermediate in the production of dyes, pigments, and other organic compounds

Secondary Uses

Corrosion inhibitor in lubricating oils, manufacturing of rubber and plastics

Hazardous Nature

Potential for causing skin and eye irritation, toxicity to aquatic life

Safety Measures

Proper handling and disposal procedures must be followed for safety and environmental protection

InChI:InChI=1/C11H11NO/c1-13-11-9-5-3-2-4-8(9)6-7-10(11)12/h2-7H,12H2,1H3

Upstream product

• 4900-62-3 2-nitro-1-methoxynaphthalene 
• 80409-51-4 2-methoxy-1-naphthoic acid amide 
• 7647-01-0 hydrogenchloride 
• 64-17-5 ethanol 
• 2036-45-5 1-methoxy-2-phenylazo-naphthalene 
• 64-19-7 acetic acid 
• 3375-23-3 2-phenylazo-1-naphthol 
• 607-24-9 2-nitro-1-naphthol 

Downstream Products

• 151560-43-9 2-Iodo-1-methoxynaphthalene 
• 934844-98-1 methyl 4-(1-methoxy-2-naphthylamino)benzoate 
• 21720-72-9 (1-methoxy-2-naphthyl)phenylamine 
• 604-60-4 2,2'-binaphthol 

Relevant academic research and scientific papers

Synthesis of Aryl Amine Derivatives from Benzyl Nitriles via Electrocyclization of in Situ Generated N-Silyl Ketene Imines

The previously unexplored reactivity of N-silyl ketene imines in organic synthesis is reported. Benzyl nitriles containing an alkenyl or aryl group at the ortho position were smoothly converted into aryl amines in good yields under two sets of mild silyla

Monna, a potent and selective blocker for transmembrane protein with unknown function 16/anoctamin-1

Transmembrane protein with unknown function 16/anoctamin-1 (ANO1) is a protein widely expressed in mammalian tissues, and it has the properties of the classic calcium-activated chloride channel (CaCC). This protein has been implicated in numerous major physiological functions. However, the lack of effective and selective blockers has hindered a detailed study of the physiological functions of this channel. In this study, we have developed a potent and selective blocker for endogenous ANO1 in Xenopus laevis oocytes (xANO1) using a drug screening method we previously established (Oh et al., 2008). We have synthesized a number of anthranilic acid derivatives and have determined the correlation between biological activity and the nature and position of substituents in these derived compounds. A structure-activity relationship revealed novel chemical classes of xANO1 blockers. The derivatives contain a-NO2 group on position 5 of a naphthyl group-substituted anthranilic acid, and they fully blocked xANO1 chloride currents with an IC 5050 of 0.08 μM for xANO1. Selectivity tests revealed that other chloride channels such as bestrophin-1, chloride channel protein 2, and cystic fibrosis transmembrane conductance regulator were not appreciably blocked by 10～30 μM MONNA. The potent and selective blockers for ANO1 identified here should permit pharmacological dissection of ANO1/CaCC function and serve as potential candidates for drug therapy of related diseases such as hypertension, cystic fibrosis, bronchitis, asthma, and hyperalgesia.

NAPHTHYL DERIVATIVES INHIBITORS OF THE BETA-AMYLOID AGGREGATION

Compounds useful in the treatment of disorders characterised by deposits of amyloid aggregates are herein described together with pharmaceutical compounds containing the same. In particular the compounds of the present invention are those having the Formula (I) as reported below. where the radicals have the meaning indicated in the description.

OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.